Vimarsana
Biggest News Aggregation in the World

Page 2 - Primary Hyperoxaluria News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Primary Hyperoxaluria. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Primary Hyperoxaluria Today - Breaking & Trending Today

Live Biotherapeutic Product (LBP) Market worth $ 2.60 billion by 2030 - Exclusive Report by InsightAce Analytic - Vimarsana News

Live Biotherapeutic Product (LBP) Market worth $ 2.60 billion by 2030 - Exclusive Report by InsightAce Analytic

/PRNewswire/ -- InsightAce Analytic Pvt. Ltd. has announced the publication of a market research report titled "Global Live Biotherapeutic Product (LBP) Market...

InsightAce Analytic Pvt. Ltd.: Live Biotherapeutic Product (LBP) Market worth $ 2.60 billion by 2030 - Vimarsana News

InsightAce Analytic Pvt. Ltd.: Live Biotherapeutic Product (LBP) Market worth $ 2.60 billion by 2030

JERSEY CITY, N.J., July 7, 2022 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. has announced the publication of a market research report titled "Global Live Biotherapeutic Product (LBP) Market

12-yr-old with rare liver disease undergoes successful multi-organ transplant in Chennai - Vimarsana News

12-yr-old with rare liver disease undergoes successful multi-organ transplant in Chennai

A 12-year-old boy with rare liver disease underwent a successful multi-organ transplant in Chennai's Gleneagles Global Health City (GGHC).

OxThera reports results from Phase 3 ePHex study with Oxabact in primary hyperoxaluria patients with maintained kidney function - Vimarsana News

OxThera reports results from Phase 3 ePHex study with Oxabact in primary hyperoxaluria patients with maintained kidney function

/PRNewswire/ -- OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announces...

Royalty Pharma Acquires OXLUMO™ Royalty Interest From Dicerna for up to $240 Million - Vimarsana News

Royalty Pharma Acquires OXLUMO™ Royalty Interest From Dicerna for up to $240 Million

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Royalty Pharma Acquires OXLUMO™ Royalty Interest From Dicerna for up to $240 Million RP Management, LLCApril 8, 2021 GMT Dicerna to receive $180 million upfront and up to $60 million in potential additional milestone payments NEW YORK and LEXINGTON, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) (“Royalty Pharma”) and Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (“Dicerna”) today announced that Royalty Pharma has acquired Dicerna’s royalty interest in OXLUMOâ...

Source: apnews.com